A Double-blind, Randomised, Incomplete Block, Crossover, Placebo-controlled, Dose-response Study to Assess Bronchial Hyperresponsiveness and Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adult Subjects With Mild to Moderate Asthma

Mundipharma Research Limited1 site in 1 country46 target enrollmentOctober 2009

ConditionsAsthma

InterventionsFluticasone propionate / Formoterol fumarate

DrugsFluticasone propionate / Formoterol fumarate

Overview

Phase: Phase 2
Intervention: Fluticasone propionate / Formoterol fumarate
Conditions: Asthma
Sponsor: Mundipharma Research Limited
Enrollment: 46
Locations: 1
Primary Endpoint: Effects of each dose strength on bronchial hyperresponsiveness to inhaled adenosine 5'-monophosphate (AMP) challenge.
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a dose-response study to determine how various measurements of airway inflammation respond to high and low dose FlutiForm®, and compared to placebo.

Detailed Description

The study consists of two 4-week treatment periods, each preceded by a 14-21 wash-out period. Subjects will be randomised to receive two of the three study treatments - FlutiForm® pMDI 50/5 µg, FlutiForm® pMDI 250/10 µg, or placebo (dummy inhaler). During the wash-out periods, subjects will take only salbutamol, if required, as rescue medication. Subjects will record a daily diary for PEFR, study medication use, rescue medication use, asthma symptom scores, and sleep disturbance due to asthma. Assessments performed at study clinic visits include inhaled adenosine 5'-monophosphate (AMP) challenge test, induced sputum test, exhaled nitric oxide (eNO) test, and spirometry tests. Safety will be assessed by lab tests, vital signs, ECG and adverse events.

Registry

clinicaltrials.gov

Start Date

October 2009

End Date

July 2010

Last Updated

7 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Mundipharma Research Limited

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female subjects aged between 18 and 55 years inclusive.
•Females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded at the screening visit prior to the first dose of study medication in each treatment period, be non-lactating, and be willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner.
•Known history of mild to moderate asthma for ≥ 6 months prior to the screening visit.
•Subject has not received systemic (injectable or oral) corticosteroid medication in the 12 weeks prior to the study screening visit.
•Demonstrate a FEV1 of ≥ 60% predicted FEV1 (Quanjer et al, 1993) at the screening visit, following appropriate withholding of asthma medications (no long-acting β2-agonist or short-acting β2-agonist/anticholinergic use 12 hours and 6 hours prior to screening, respectively).
•Demonstrate AMP challenge PC20FEV1 \< 60 mg/mL, following appropriate withholding of asthma medication (no short-acting bronchodilator use 6 hours prior to the AMP challenge test at Visit 2).
•Non-smoker for at least 12 months prior to study screening. Ex-smokers must have a smoking history equivalent to less than "10 pack years" (i.e. at least 1 pack of 20 cigarettes per day for 10 years or 10 packs per day for 1 year, etc.).
•Demonstrate satisfactory technique in the use of the pMDI.
•Willing and able to enter information in the diary and attend all study visits.
•Willing and able to substitute study medication for their pre-study prescribed asthma medication for the duration of the study.

Exclusion Criteria

•Near fatal or life-threatening (including intubation) asthma within the past year.
•Hospitalisation or an emergency visit for asthma within 4 weeks prior to the screening visit.
•History of omalizumab use within the past 6 months.
•Current evidence or history of any clinically significant disease or abnormality including uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia. 'Clinically significant' is defined as any disease that, in the opinion of the Investigator, would put the subject at risk through study participation, or which would affect the outcome of the study.
•In the investigator's opinion a clinically significant upper or lower respiratory infection within 4 weeks prior to the screening visit.
•Significant, non-reversible, active pulmonary disease (e.g. chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, tuberculosis).
•Known Human Immunodeficiency Virus (HIV)-positive status.
•Current evidence or history of alcohol and/or substance abuse within 12 months prior to the screening visit.
•Subjects who have taken beta-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole (Hismanal), quinidine type antiarrhythmics, or potent CYP 3A4 inhibitors such as ketoconazole within one week prior to the screening visit.
•History of leukotriene receptor antagonist use, e.g. montelukast, within one week prior to the screening visit.

Arms & Interventions

Fluticasone propionate / Formoterol fumarate

Intervention: Fluticasone propionate / Formoterol fumarate

Fluticasone propionate / Formoterol fumarate placebo

Intervention: Fluticasone propionate / Formoterol fumarate

Outcomes

Primary Outcomes

Effects of each dose strength on bronchial hyperresponsiveness to inhaled adenosine 5'-monophosphate (AMP) challenge.

Secondary Outcomes

eNO, % of eosinophils in induced sputum, comp each dose placebo of bronchial hyperresponsive to AMP challenge. Lung func, rescue med use, asthma symps,& exacerbations sleep disturbance, discon due to lack of efficacy & spontaneously reported AEs.